Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19887647 
Ma Y, et al. (2010) BRCA1 regulates acetylation and ubiquitination of estrogen receptor-alpha. Mol Endocrinol 24, 76-90 19887647
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S118-p - ER-alpha (human)
Orthologous residues
ER‑alpha (human): S118‑p, ER‑alpha (mouse): S122‑p, ER‑alpha (rat): S123‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  DU 145 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  acetylation
 Comments:  modulate the ability of BRCA1 to block acetylation of ER-alpha

S167-p - ER-alpha (human)
Orthologous residues
ER‑alpha (human): S167‑p, ER‑alpha (mouse): S171‑p, ER‑alpha (rat): S172‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  DU 145 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Downstream Regulation
 Effect of modification (function):  acetylation
 Comments:  modulate the ability of BRCA1 to block acetylation of ER-alpha

K266-ac - ER-alpha (human)
Orthologous residues
ER‑alpha (human): K266‑ac, ER‑alpha (mouse): K270‑ac, ER‑alpha (rat): K271‑ac
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  DU 145 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BRCA1 (human) decrease
Downstream Regulation
 Effect of modification (function):  activity, induced
 Effect of modification (process):  transcription, altered
 Comments:  K266/268Q or K266/268R mutations confer resistance to repression by BRCA1

K268-ac - ER-alpha (human)
Orthologous residues
ER‑alpha (human): K268‑ac, ER‑alpha (mouse): K272‑ac, ER‑alpha (rat): K273‑ac
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  prostate cancer
 Relevant cell lines - cell types - tissues:  DU 145 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BRCA1 (human) decrease
Downstream Regulation
 Effect of modification (function):  activity, induced
 Effect of modification (process):  transcription, altered
 Comments:  K266/268Q or K266/268R mutations confer resistance to repression by BRCA1

K302-ac - ER-alpha (human)
Orthologous residues
ER‑alpha (human): K302‑ac, ER‑alpha (mouse): K306‑ac, ER‑alpha (rat): K307‑ac
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  breast cancer, prostate cancer
 Relevant cell lines - cell types - tissues:  DU 145 (prostate cell), MDA-MB231 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BRCA1 (human) no change compared to control

K302-ub - ER-alpha (human)
Orthologous residues
ER‑alpha (human): K302‑ub, ER‑alpha (mouse): K306‑ub, ER‑alpha (rat): K307‑ub
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
UBIQUITIN LIGASE BRCA1 (human)
Downstream Regulation
 Effect of modification (function):  activity, inhibited
 Effect of modification (process):  transcription, altered
 Comments:  K302/303A mutants are more active then wt protein at low concentration of E2

K303-ac - ER-alpha (human)
Orthologous residues
ER‑alpha (human): K303‑ac, ER‑alpha (mouse): K307‑ac, ER‑alpha (rat): K308‑ac
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  breast cancer, prostate cancer
 Relevant cell lines - cell types - tissues:  DU 145 (prostate cell), MDA-MB231 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
BRCA1 (human) no change compared to control
Downstream Regulation
 Effect of modification (function):  activity, inhibited
 Effect of modification (process):  transcription, altered
 Comments:  K302/303A mutants are more active then wt protein at low concentration of E2


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.